[Skip to Content]
[Skip to Content Landing]
November 2, 2011

Detours on the Road to Personalized MedicineBarriers to Biomarker Validation and Implementation

Author Affiliations

Author Affiliations: Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Jamaica Plain, Massachusetts (Drs Fiore and D’Avolio); Boston University Schools of Medicine and Public Health, Boston, Massachusetts (Dr Fiore); and Division of Aging, Harvard Medical School and Center for Surgery and Public Health, Brigham and Women's Hospital, Boston (Dr D’Avolio).

JAMA. 2011;306(17):1914-1915. doi:10.1001/jama.2011.1605

The sequencing of the human genome, the ability to perform genome-wide association studies, and the development of high-throughput nucleotide sequencing support the goals of personalized medicine. “Next generation” sequencing platforms now provide much higher resolution of DNA than was possible with microarray-based–single nucleotide polymorphism (SNP) detection. Other breakthrough technologies such as the ability to sequence DNA from single cells, targeted mRNA molecules, and methylated regions of DNA; DNA fragment length analysis; isolation of circulating tumor cells; and the ability to use paraffin-embedded tissue for mRNA sequencing will make genotyping faster, easier, less expensive, better, and ultimately more readily available.

First Page Preview View Large
First page PDF preview
First page PDF preview